<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Regulatory T Cells in CLL - Immune System Exhaustion and Potential Restoration, and the Role of Immuno-Oncology Therapies

Aug 4, 2022 11:15:00 AM / by Champions Oncology posted in Immuno-Oncology, Hematological Malignancies

Chronic lymphocytic leukemia (CLL) is one of the most commonly occurring hematologic malignances with no known cure and is defined by the clonal expansion and accumulation of CD5+ B cells in the blood and bone marrow. Standard treatments to manage disease include chemotherapy and rituximab (anti-CD20 monoclonal antibody). Newer therapies that are less prone to resistance or treatment failure are currently being examined, such as Bruton tyrosine kinase (BTK) inhibitors and anti-CD20 biosimilars[1],[2].

Read More →